Cumulative Days of Musculoskeletal Improvement in Bio-Naïve Patients With PsA With or Without Metabolic Syndrome and Obesity Receiving Risankizumab Through Week 244: Integrated Results From the KEEPsAKE Clinical Trials (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1310; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Bio-naïve patients with PsA receiving RZB displayed over 1000 days of estimated mean cumulative joint and pain response over 244 weeks, and over 900 days of LDA/REM, suggesting durable musculoskeletal outcomes. Similar cumulative responses were seen in those with or without MetS or elevated BMI, indicating RZB's long-term utility in PsA populations with these comorbidities. 1."
Clinical • Genetic Disorders • Immunology • Inflammatory Arthritis • Metabolic Disorders • Musculoskeletal Diseases • Obesity • Psoriatic Arthritis • Seronegative Spondyloarthropathies • IL23A
|
|
Saakshi Khattri1; Shikha Singla2; Viviane de Souza3; Jamie Vora4; BOUSSAD AIT-CHALLAL4; Zhiyuan Du4; Thomas Iyile4; William Tillett5
|